Literature DB >> 11472696

Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS).

H R Chandra1, N Choudhary, C O'Neill, J Boura, G C Timmis, W W O'Neill.   

Abstract

Previous studies have shown higher levels of Chlamydia pneumoniae (C. pneumoniae, CP) antibody titers (CPIgG), C-reactive protein (CRP), and fibrinogen in patients with coronary artery disease. The role of these infectious and inflammatory markers in precipitating acute coronary syndrome (ACS) is unclear. We conducted a cross-sectional study on patients (n = 830, mean age 63 +/- 15 years, 57% male) admitted to the chest pain center of our institution. The differences in the CPIgG, CRP, and fibrinogen levels in patients who were diagnosed with ACS versus those who were not (non-ACS) were evaluated. CPIgG titers tended to be higher in the ACS group than in the non-ACS group. However, when different titers were used to define seropositivity, the difference achieved statistical significance only at the titer of > or =1:1,024 (35% vs 26%, p = 0.004). CRP (median 0.48 vs 0.33 mg/dl, p <0.0001), fibrinogen (median 317 vs 293 mg/dl, p <0.0001), and leukocyte count (median 7.7 vs 6.9 10(9)/L, p <0.0001) were higher in the ACS group. On multivariate analysis, CPIgG > or =1:1,024 (odds ratio [OR] 1.62), diabetes (OR 1.91), hypertension (OR 1.46), prior myocardial infarction (OR 1.78), smoking (OR 1.70), Caucasian race (OR 1.7), high-density lipoprotein (OR 0.98), and elevated troponin-T (OR 12.44) were the only factors independently associated with ACS. Thus, we found a strong association between high level seropositivity to CP and ACS. This may indicate recent re-infection or an exaggerated immune response to CP as an etiologic factor for ACS. This study also suggests that therapeutic interventions may need to be specifically targeted to these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472696     DOI: 10.1016/s0002-9149(01)01628-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 3.  CD14 and toll-like receptor 4: a link between infection and acute coronary events?

Authors:  R Arroyo-Espliguero; P Avanzas; S Jeffery; J C Kaski
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

4.  Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis.

Authors:  V Y Hoymans; J M Bosmans; L Van Renterghem; R Mak; D Ursi; F Wuyts; C J Vrints; M Ieven
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

5.  The seroepidemiology of the chronic infections in patients with myocardial infarction in North of Iran.

Authors:  Hadi Bazzazi; Ezzat Allah Ghaemi; Mohammad Ali Ramezani
Journal:  J Res Med Sci       Date:  2010-03       Impact factor: 1.852

6.  Lack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteries.

Authors:  Markus Ferrari; Gerald S Werner; Barbara M Richartz; Albrecht Oehme; Eberhard Straube; Hans R Figulla
Journal:  Cardiovasc Ultrasound       Date:  2005-04-27       Impact factor: 2.062

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.